Vaccination strategies that can induce a broad spectrum immune response are important to
enhance protection against SARS-CoV-2 variants. We conducted a randomized, double …

Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …

Background We assessed the safety and immunogenicity of a recombinant adenovirus type-
5 (Ad5)–vectored coronavirus disease 2019 (COVID-19) vaccine with homologous prime …

Introduction The waning antibody levels several months after prime vaccination and the
persistent epidemics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Background In partial response to the coronavirus disease 2019 (COVID-19) pandemic,
countries around the world are conducting large-scale vaccination campaigns. Real-world …

Background This is the first randomised controlled trial for assessment of the
immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored …

Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess
the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) …

Background The certification of immunogenicity consistency at different production scales is
indispensable for the quality control of vaccines. Research design and methods A …

Accepted Manuscript Page 1 Accepted Manuscript © The Author(s) 2021. Published by Oxford
University Press for the Infectious Diseases Society of America. All rights reserved. For …

Background Heterologous boost vaccination has been proposed as an option to elicit
stronger and broader, or longer-lasting immunity. We assessed the safety and …